Honolulu Star-Advertiser

Tuesday, October 15, 2024 87° Today's Paper


Top News

FDA OKs third antibody drug for COVID-19 cases

WASHINGTON >> U.S. health officials have granted emergency authorization to a third antibody drug to help reduce hospitalizations and deaths due to COVID-19.

The FDA said today it authorized the drug from GlaxoSmithKline and Vir Biotechnology for people with mild-to-moderate cases of COVID-19 who face extra risks of severe illness, including seniors and those with underlying health problems.

There has been low demand for two similar drugs already available, due mainly to the logistical hurdles of delivering them and confusion about their availability. U.S. health officials have been trying to raise awareness of the treatments, connecting people who test positive for COVID-19 with information about nearby providers.

The drugs are delivered as a one-time intravenous infusion at a hospital or clinic and should be given within 10 days of the start of symptoms.

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines. Having trouble with comments? Learn more here.